Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis

Oncotarget

Volumn 7, Issue 24, 2016, Pages 36382-36394

  Yang, Xiaojuan ^a,b,c   Pang, Jiuxia ^a   Shen, Na ^a   Yan, Fei ^a   Wu, Lai Chu ^b   Al Kali, Aref ^c   Litzow, Mark R ^c   Peng, Yong ^d   Lee, Robert J ^b   Liu, Shujun ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d SICHUAN UNIVERSITY   (China)

Author keywords

BCR ABL; Bortezomib; Chronic myeloid leukemia; Liposome; Nanoparticle

Indexed keywords

BCR ABL PROTEIN; BORTEZOMIB; DOXORUBICIN; TRANSCRIPTION FACTOR SP1; ANTINEOPLASTIC AGENT; BCR PROTEIN, HUMAN; BREAKPOINT CLUSTER REGION PROTEIN; LIPOSOME; SP1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; ELIMINATION HALF-LIFE; ENZYME ACTIVITY; LIPOSOMAL DELIVERY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; ONCOGENE; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; TRANSCRIPTION FACTOR SP1 GENE; VOLUME OF DISTRIBUTION; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; K-562 CELL LINE; KAPLAN MEIER METHOD; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORTEZOMIB; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIPOSOMES; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, INBRED NOD; MICE, SCID; PROTO-ONCOGENE PROTEINS C-BCR; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR;

EID: 84978153974     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8871     Document Type: Article

References (28)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. The New England journal of medicine. 1999; 341:164-172
2. Burgess DJ. Leukaemia: targeted therapy re-enABLed? Nature reviews cancer. 2011; 11:460
3. Zhao F, Mancuso A, Bui TV, Tong X, Gruber JJ, Swider CR, Sanchez PV, et al. Thompson, Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene. 2010; 29:2962-2972
4. Marega M, Piazza RG, Pirola A, Redaelli S, Mogavero A, Iacobucci I, Meneghetti I, Parma M, Pogliani EM, Gambacorti-Passerini C. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2010; 24: 1445-1449
5. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. The New England journal of medicine. 2001; 344:1038-1042
6. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia, The New England journal of medicine. 2003; 348:994-1004
7. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. The New England journal of medicine. 2003; 349:1423-1432
8. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nature reviews drug discovery. 2004; 3:1001-1010
9. Bianchini M, De Brasi C, Gargallo P, Gonzalez M, Bengio R, Larripa I. Specific assessment of BCRABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients. European journal of haematology. 2009; 82:292-300
10. Morinaga K, Yamauchi T, Kimura S, Maekawa T, Ueda T. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification. International journal of cancer. Journal international du cancer. 2008; 122:2621-2627
11. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293:876-880
12. Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer research. 2005; 65:8912-8919
13. Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood. 2004; 104:509-518
14. Jagani Z, Song K, Kutok JL, Dewar MR, Melet A, Santos T, Grassian A, Ghaffari S, Wu C, Yeckes-Rodin H, Ren R, Miller K, Khosravi-Far R. Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer research. 2009; 69:6546-6555
15. Santos FP, Kantarjian H, McConkey D, O'Brien S, Faderl S, Borthakur G, Ferrajoli A, Wright J, Cortes J. Pilot study of bortezomib for patients with imatinibrefractory chronic myeloid leukemia in chronic or accelerated phase. Clinical lymphoma, myeloma & leukemia. 2011; 11:355-360
16. Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons, Current oncology reports. 2001; 3:156-162
17. Porche DJ. Liposomal doxorubicin (Doxil), The Journal of the Association of Nurses in AIDS Care. JANAC. 1996; 7:55-59
18. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009; 113:6411-18
19. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010; 17:333-347
20. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood. 2008; 111:2364-2373
21. Frank O, Brors B, Fabarius A, Li L, Haak M, Merk S, Schwindel U, Zheng C, Muller MC, Gretz N, Hehlmann R, Hochhaus A, Seifarth W. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia. 2006; 20:1400-1407
22. Keeshan K, Mills KI, Cotter TG, McKenna SL. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia. 2001;15:1823-1833
23. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010; 107:7473-7478
24. Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012; 119:6025-6031
25. O'Byrne KJ, Barr MP, Gray SG. The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer. Cancers. 2011; 3:1426-1453
26. Miller AA, Pang H, Hodgson L, Ramnath N, Otterson GA, Kelley MJ, Kratzke RA, Vokes EE. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2010; 5:380-384
27. Gao XN, Yan F, Lin J, Gao L, Lu XL, Wei SC, Shen N, Pang JX, Ning QY, Komeno Y, Deng AL, et aj. AML1/ETO cooperates with HIF1alpha to promote leukemogenesis through DNMT3a transactivation. Leukemia. 2015; 29:1730-1740
28. Barth RF, Adams DM, Soloway AH, Mechetner EB, Alam F, Anisuzzaman AK. Determination of boron in tissues and cells using direct-current plasma atomic emission spectroscopy. Analytical chemistry. 1991; 63:890-893